Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A phase Ib/II study of ivosidenib with venetoclax plus /- azacitidine in IDH1-mutated myeloid malignancies.

Conference paper

Lachowiez CA. et al, (2021), JOURNAL OF CLINICAL ONCOLOGY, 39

Oncogenic Gata1 causes stage-specific megakaryocyte differentiation delay.

Journal article

Juban G. et al, (2021), Haematologica, 106, 1106 - 1119

Mechanisms of Response and Resistance to AML Therapies.

Journal article

Stoilova B. et al, (2020), Clin Lymphoma Myeloma Leuk, 20 Suppl 1

OncogenicGata1causes stage-specific megakaryocyte differentiation delay

Journal article

Juban G. et al, (2019), Haematologica: the hematology journal

The Inflammasome: More Than a Protective Innate Immune Mechanism.

Journal article

Stoilova B. and Vyas P., (2019), Immunity, 51, 3 - 5

Clonal heterogeneity of acute myeloid leukemia treated with the IDH2 inhibitor enasidenib.

Journal article

Quek L. et al, (2018), Nat Med, 24, 1167 - 1177

Single-cell analysis reveals the continuum of human lympho-myeloid progenitor cells.

Journal article

Karamitros D. et al, (2018), Nat Immunol, 19, 85 - 97

Impact of Mutant Haemopoietic Transcription Factor GATA1s on Haemopoiesis

Conference paper

Vyas P. et al, (2017), BLOOD, 130

Load More